← Back to Clinical Trials
Recruiting NCT04611516
NCT04611516 The Ear-Nose-Throat (ENT) Prospective International Cohort of PCD Patients (EPIC-PCD)
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT04611516 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Bern |
| Condition | Primary Ciliary Dyskinesia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-03-02 |
| Primary Completion | 2030-12 |
Trial Parameters
Condition Primary Ciliary Dyskinesia
Sponsor University of Bern
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2020-03-02
Completion 2030-12
All Conditions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The Ear-Nose-Throat (ENT) Prospective International Cohort of patients with Primary Ciliary Dyskinesia (EPIC-PCD) is a prospective observational clinical cohort study, set up as a multinational multi-centre study. It is embedded into routine patient care of participating reference centres for PCD and patients keep being managed according to local procedures and guidelines.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of PCD (clinical and test certified) * Patient must undergo an ENT examination minimum once a year as part of their clinical follow-up Exclusion Criteria: None
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology